Drugs / Hesperidin
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04452799 | Jul → Oct 2020 | COVID-19 | Tanta University | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT00983086 | Aug 2007 → Feb 2008 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06546111 | Oct 2024 → Oct 2025 overdue | Helicobacter pylori infectious disease | Sadat City University | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05243706 | Mar 2022 → Sep 2023 | poisoning | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT01110512 | Oct → Dec 2010 | chronic venous insufficiency | Azidus Brasil | Unknown | No outcome recorded |
| Phase 3 | NCT00330096 | Mar 2006 → Apr 2009 | osteoporosis | Nestlé | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT07598214 | Feb 2025 → Nov 2026 expected | cancer, familial, with in vitro Radioresistance | Beni-Suef University | Recruiting | No outcome recorded |
| Phase 4 | NCT06579482 | Nov 2024 → May 2025 | chronic venous insufficiency | Fundação Educacional Serra dos Órgãos | Completed | No outcome recorded |
| Phase 4 | NCT07588828 | Oct 2024 → Feb 2026 | female breast carcinoma | Ittefaq Hospital trust | Completed | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 2 | NCT04715932 Comparator | Feb → May 2021 | COVID-19, anosmia, headache disorder | Montreal Heart Institute | Completed | No outcome recorded |
| Phase 2 | NCT01773486 Comparator | Jun → Dec 2015 | obesity disorder | University of Maryland, Baltimore | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT00914251 Comparator | Nov 2008 → Mar 2009 | metabolic syndrome X | University of Rome Tor Vergata | Unknown | No outcome recorded |
| Phase 3 | NCT06811220 Comparator | Jan → Dec 2025 overdue | breast cancer | Alexandria University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05756179 Comparator | Jul 2023 → Sep 2025 overdue | rheumatoid arthritis | Alexandria University | Recruiting | No outcome recorded |
| Phase 3 | NCT01477281 Comparator | Feb → Jul 2012 | chronic venous insufficiency | Laboratório Teuto Brasileiro S/A | Unknown | No outcome recorded |
| Phase 4 | NCT03471910 Comparator | Jun 2017 → Mar 2018 | venous insufficiency | Fundação Educacional Serra dos Órgãos | Completed | No outcome recorded |
| — | NCT04933591 Comparator | Sep 2020 → Aug 2021 | varicose disease | Pirogov Russian National Research Medical University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hesperidin | “Patients will receive standard triple therapy (Omeprazole 20 mg cap PO BID + Clarithromycin 500 mg tab PO BID + Amoxicillin 1000 mg PO BID) and Diosmin/Hesperidin (Daflon)...” NCT06546111 ↗16“Daflon® (50 mg Hesperidin and Micronized purified flavonoid fraction (MPFF) 450 diosmin combination one film coated tablet)” NCT06811220 ↗ “Diosmin 450mg and Hesperidin 50mg Tablets in Chronic Venous Insufficiency After 3 Months of Therapy” NCT06579482 ↗ “500 ml control drink plus hesperidin or 500 ml control drink and placebo.” PMID 22110589 ↗ Nov 2011 “combination of Diosmin and Hesperidin” NCT07598214 ↗ “Diosmin (450 mg) + hesperidin (50 mg)” NCT01110512 ↗ |
| Action | Inhibit | “hesperidin may disrupt the interaction of ACE2 with RBD of SARS-CoV-2 thus block its entry into the lung cells” NCT04452799 ↗ |
| Modality | Small molecule | “a flavonoid such as hesperidin” NCT00330096 ↗ |
| Route | Oral | “The women are randomised to consume 2 servings of hesperidin-rich food” NCT00330096 ↗ |
| Target | ACE2 | “hesperidin may disrupt the interaction of ACE2 with RBD of SARS-CoV-2 thus block its entry into the lung cells” NCT04452799 ↗ |